{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:17:07Z","timestamp":1790245027780,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.pbb.2013.10.022","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T01:30:18Z","timestamp":1383528618000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents"],"prefix":"10.1016","volume":"114-115","author":[{"given":"Koji","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2013.10.022_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A2A receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2013.10.022_bb0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(94)90033-7","article-title":"Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression","volume":"262","author":"D'Aquila","year":"1994","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.pbb.2013.10.022_bb0020","first-page":"375","article-title":"Animal models of depression","volume":"3","author":"Deussing","year":"2006","journal-title":"Drug Discov Today: Dis Model"},{"key":"10.1016\/j.pbb.2013.10.022_bb0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archneur.1992.00530270125028","article-title":"An estimate of the incidence of depression in idiopathic Parkinson\u2019s disease","volume":"49","author":"Dooneief","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pbb.2013.10.022_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0083-6729(10)82001-1","article-title":"Models of depression","volume":"82","author":"Duman","year":"2010","journal-title":"Vitam Horm"},{"issue":"1","key":"10.1016\/j.pbb.2013.10.022_bb0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjp.0704240","article-title":"Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice","volume":"134","author":"El Yacoubi","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"11 Suppl. 6","key":"10.1016\/j.pbb.2013.10.022_bb0040","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1212\/01.WNL.0000095220.87550.F6","article-title":"Adenosine A2A receptors and depression","volume":"61","author":"El Yacoubi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2013.10.022_bb0045","first-page":"4","article-title":"Augmentation and combination strategies in treatment-resistant depression","volume":"62","author":"Fava","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2013.10.022_bb0050","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.npp.1300884","article-title":"Clinical and biological effects of mifepristone treatment for psychotic depression","volume":"31","author":"Flores","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2013.10.022_bb0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2013.10.022_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brainres.2010.08.078","article-title":"Pharmacological characterization of repeated corticosterone injection-induced depression model in rats","volume":"1359","author":"Iijima","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2013.10.022_bb0065","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archpsyc.61.12.1235","article-title":"Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial","volume":"61","author":"Jahn","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.10.022_bb0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-2999(87)90357-8","article-title":"Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression","volume":"134","author":"Kennett","year":"1987","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2013.10.022_bb0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0091-3057(01)00625-6","article-title":"Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test","volume":"71","author":"Kitamura","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2013.10.022_bb0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(00)00745-7","article-title":"Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats","volume":"408","author":"Koga","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2013.10.022_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1331.2008.02058.x","article-title":"Depressive symptoms in Parkinson's disease","volume":"15","author":"Lemke","year":"2008","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.pbb.2013.10.022_bb0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"6002-US-005 Study Group. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \"off\" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pbb.2013.10.022_bb0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0006-3223(03)00530-4","article-title":"Prevalence, etiology, and treatment of depression in Parkinson's disease","volume":"54","author":"McDonald","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.10.022_bb0100","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1192\/bjp.142.5.508","article-title":"L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation","volume":"142","author":"Mendlewicz","year":"1983","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pbb.2013.10.022_bb0105","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","article-title":"Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study","volume":"25","author":"Mizuno","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.pbb.2013.10.022_bb0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2013.10.022_bb0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0006-3223(00)01088-X","article-title":"Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment","volume":"49","author":"Pariante","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.10.022_bb0135","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.pbb.2013.10.022_bb0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pbb.2013.10.022_bb0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2013.10.022_bb1000","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endo.133.1.8391426","article-title":"Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system","volume":"133","author":"Reul","year":"1993","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.pbb.2013.10.022_bb0155","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.49.4.1168","article-title":"A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group","volume":"49","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2013.10.022_bb0160","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00210-013-0897-5","article-title":"In vitro pharmacological profile of the A2A receptor antagonist istradefylline","volume":"386","author":"Saki","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pbb.2013.10.022_bb0165","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00008877-199312000-00008","article-title":"Neuroanatomical basis for the antidepressant-like effects of the 5-HT1A receptor agonists 8-OH-DPAT and ipsapirone in the rat forced swimming test","volume":"4","author":"Schreiber","year":"1993","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2013.10.022_bb0175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s002130051146","article-title":"Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP","volume":"147","author":"Shiozaki","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2013.10.022_bb0180","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","article-title":"A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease","volume":"70","author":"Stacy","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pbb.2013.10.022_bb0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2013.10.022_bb0190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12264-010-0323-7","article-title":"Behavioral animal models of depression","volume":"26","author":"Yan","year":"2010","journal-title":"Neurosci Bull"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713002682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713002682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T19:36:20Z","timestamp":1564601780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305713002682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":33,"alternative-id":["S0091305713002682"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2013.10.022","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2013.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}